These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 15725921)

  • 1. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
    Kumar R; Alavi A
    Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorodeoxyglucose-PET in the management of malignant melanoma.
    Kumar R; Mavi A; Bural G; Alavi A
    Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
    Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
    Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of positron emission tomography in the management of cutaneous melanoma.
    Friedman KP; Wahl RL
    Semin Nucl Med; 2004 Oct; 34(4):242-53. PubMed ID: 15493002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
    Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of clinical impact of
    Liu J; Larcos G; Howle J; Veness M
    Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
    Clark PB; Soo V; Kraas J; Shen P; Levine EA
    Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
    Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
    J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of positron emission tomography for the detection of melanoma metastases.
    Holder WD; White RL; Zuger JH; Easton EJ; Greene FL
    Ann Surg; 1998 May; 227(5):764-9; discussion 769-71. PubMed ID: 9605668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma.
    Bastiaannet E; Hoekstra HJ; Hoekstra OS
    Methods Mol Biol; 2011; 727():123-39. PubMed ID: 21331932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
    Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma.
    Uren RF; Howman-Giles R; Chung D; Thompson JF
    J Surg Oncol; 2011 Sep; 104(4):405-19. PubMed ID: 21858836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET in early stage cutaneous malignant melanoma.
    McIvor J; Siew T; Campbell A; McCarthy M
    J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of lymph node ultrasound and whole body
    Stahlie EHA; van der Hiel B; Bruining A; van de Wiel B; Schrage YM; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Eur J Surg Oncol; 2021 May; 47(5):1157-1162. PubMed ID: 33353826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.
    Rodriguez Rivera AM; Alabbas H; Ramjaun A; Meguerditchian AN
    Surg Oncol; 2014 Mar; 23(1):11-6. PubMed ID: 24556310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma.
    Havenga K; Cobben DC; Oyen WJ; Nienhuijs S; Hoekstra HJ; Ruers TJ; Wobbes T
    Eur J Surg Oncol; 2003 Oct; 29(8):662-4. PubMed ID: 14511614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial staging of malignant melanoma by positron emission tomography and sentinel node biopsy.
    Libberecht K; Husada G; Peeters T; Michiels P; Gys T; Molderez C
    Acta Chir Belg; 2005; 105(6):621-5. PubMed ID: 16438072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
    Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.